Steven J. Lemery
MD, MHS
Associate Director, Oncology Center of Excellence
👥Biography 个人简介
Steven Lemery has contributed to tissue agnostic FDA oncology approvals including pembrolizumab for MSI-high and larotrectinib for NTRK fusion positive tumors. His work has helped define regulatory frameworks for basket trials and biomarker-defined populations. He has shaped modern tissue agnostic approval methodology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Steven J. Lemery 的研究动态
Follow Steven J. Lemery's research updates
留下邮箱，当我们发布与 Steven J. Lemery（US Food and Drug Administration）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment